%0 Journal Article
%A Baertsch, Marc-Andrea
%A Fougereau, Mathilde
%A Hielscher, Thomas
%A Sauer, Sandra
%A Breitkreutz, Iris
%A Jordan, Karin
%A Müller-Tidow, Carsten
%A Goldschmidt, Hartmut
%A Raab, Marc-Steffen
%A Hillengass, Jens
%A Giesen, Nicola
%T Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma.
%J Cancers
%V 13
%N 18
%@ 2072-6694
%C Basel
%I MDPI
%M DKFZ-2021-02189
%P 4706 
%D 2021
%Z #LA:A360#
%X Salvage high-dose chemotherapy and autologous stem cell transplantation (HDCT/ASCT) is a treatment option for relapsed and/or refractory multiple myeloma (RRMM). No data are available on salvage HDCT/ASCT following re-induction treatment with state-of-the-art triplet regimens. We retrospectively report on 44 patients receiving salvage HDCT/ASCT following re-induction with carfilzomib/lenalidomide/dexamethasone (KRd). All patients received frontline HDCT/ASCT with median time to progression (TTP1) of 2.9 (1.2-13.5) years, enabling paired comparison of frontline and salvage HDCT/ASCT. After re-induction and before salvage transplant, 25/44 patients (57
%K lenalidomide maintenance (Other)
%K multiple myeloma (Other)
%K salvage autologous stem cell transplantation (Other)
%K salvage high-dose chemotherapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34572934
%2 pmc:PMC8472377
%R 10.3390/cancers13184706
%U https://inrepo02.dkfz.de/record/176949